Expression of PD-L1 by these diverse stromal elements has both overlapping and non-redundant roles in immune-mediated tumor control, particularly in the context of therapies targeting the PD-1/PD-L1 inhibitory axis [3,4]. Here, CD274 is linked to neoplasm.